Mycophenolate mofetil in multiple sclerosis: A multicentre retrospective study on 344 patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 3, 2014, Pages 279-283

  Michel, L ^a   Vukusic, S ^b,c,d   De Seze, J ^e   Ducray, F ^b,c,d   Ongagna, J C ^e   Lefrere F ^a   Jacq Foucher, M ^a   Confavreux, C ^b,c,d   Wiertlewski, S ^a   Laplaud, D A ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c LYON NEUROSCIENCE RESEARCH CENTER   (France)

^d UNIVERSITÉ LYON 1   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ALOPECIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EDEMA; EXPANDED DISABILITY STATUS SCALE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

MULTIPLE SCLEROSIS;

ADULT; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MITOXANTRONE; MULTIPLE SCLEROSIS; MYCOPHENOLIC ACID; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84896698123     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305298     Document Type: Article

References (19)

1. Barten MJ, van Gelder T, Gummert JF, et al. Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. Transpl Immunol 2002;10:1-14. (Pubitemid 34863319)
2. Stosic-Grujicic S, Maksimovic-Ivanic D, Miljkovic D, et al. Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue. Transplant Proc 2002;34:2955-7. (Pubitemid 35304980)
3. Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999;31:1250-2. (Pubitemid 29127892)
4. Becker BN. Mycophenolate mofetil. Transplant Proc 1999;31:2777-8. (Pubitemid 29525648)
5. Neurath MF, Wanitschke R, Peters M, et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44:625-8. (Pubitemid 29195908)
6. Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002;41:876-82.
7. Waiser J, Budde K, Braasch E, et al. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis 1999;34:e9.
8. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001;56:94-6. (Pubitemid 32059658)
9. Schneider C, Gold R, Schafers M, et al. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002;25:286-8. (Pubitemid 34117079)
10. Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011;76:1168-72.
11. Confavreux C, Moreau T. Emerging treatments in multiple sclerosis: azathioprine and mofetil. Mult Scler 1996;1:379-84. (Pubitemid 126701302)
12. Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001;248:713-4. (Pubitemid 32695873)
13. Frohman EM, Brannon K, Racke MK, et al. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol. 2004;27:80-3. (Pubitemid 38569179)
14. Remington GM, Treadaway K, Frohman T, et al. A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). Ther Adv Neurol Disord 2010;3:3-13.
15. Frohman EM, Cutter G, Remington G, et al. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2010;3:15-28.
16. Vermersch P, Waucquier N, Michelin E, et al. Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007;14:85-9. (Pubitemid 46088042)
17. Confavreux C, Compston DA, Hommes OR, et al. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:671-6.
18. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
19. Portaccio E, Zipoli V, Siracusa G, et al. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients. Eur Neurol 2009;61:177-82.